Geron Corporation
Geron develops RYTELO (imetelstat), an oligonucleotide telomerase inhibitor approved in the U.S.
10-QNov 12Latest SEC filing
Nov 6Latest story
Geron develops RYTELO (imetelstat), an oligonucleotide telomerase inhibitor approved in the U.S.
November 2026
October 2026
August 2026